Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic or Locally Advanced Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00817362
What this trial is testing

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast CancerHER2 Positive Breast CancerMetastatic Breast Cancer+1 more
Infinity Pharmaceuticals, Inc. 29
Large-scale testing (Phase 3)UnknownNCT00532727
What this trial is testing

Triple Negative Breast Cancer Trial

Who this might be right for
Breast Cancer
Institute of Cancer Research, United Kingdom 400
Large-scale testing (Phase 3)Active Not RecruitingNCT05382286
What this trial is testing

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerPD-L1 Positive
Gilead Sciences 443
Testing effectiveness (Phase 2)Looking for participantsNCT06584227
What this trial is testing

Adebrelimab and Chidamide for Pancreatic Cancer

Who this might be right for
Pancreatic Cancer, Adult
Liu Xiufeng 45
Early research (Phase 1)WithdrawnNCT06681870
What this trial is testing

ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

Who this might be right for
CLDN6-positive Solid TumorOvarian CancerEndometrial Cancer+3 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Study completedNCT00344773
What this trial is testing

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Pulmonary Cancer
AstraZeneca 46
Early research (Phase 1)UnknownNCT03774979
What this trial is testing

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Who this might be right for
Solid Tumor
Jiangsu HengRui Medicine Co., Ltd. 193
Testing effectiveness (Phase 2)Study completedNCT02964559
What this trial is testing

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Who this might be right for
Recurrent Skin CarcinomaSkin Squamous Cell Carcinoma
Emory University 11
Testing effectiveness (Phase 2)Ended earlyNCT03138083
What this trial is testing

OMO-1 in Solid Malignancies

Who this might be right for
Neoplasms
Octimet Oncology N.V. 40
Large-scale testing (Phase 3)Study completedNCT00924989
What this trial is testing

OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

Who this might be right for
Adrenocortical Carcinoma
Astellas Pharma Inc 139
Post-approval studies (Phase 4)UnknownNCT04554524
What this trial is testing

Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma

Who this might be right for
Thymoma and Thymic Carcinoma
Tang-Du Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03601455
What this trial is testing

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Who this might be right for
Bladder Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Stage IVA Bladder Cancer AJCC v8+1 more
Jonsson Comprehensive Cancer Center 13
Testing effectiveness (Phase 2)UnknownNCT05989425
What this trial is testing

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Fudan University 32
Early research (Phase 1)Looking for participantsNCT06880549
What this trial is testing

MRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

Who this might be right for
Advanced Solid Tumors
ModernaTX, Inc. 42
Testing effectiveness (Phase 2)Ended earlyNCT00470249
What this trial is testing

Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
University of Southampton 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06435455
What this trial is testing

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 126
Testing effectiveness (Phase 2)UnknownNCT00995358
What this trial is testing

A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer

Who this might be right for
Esophageal Cancer
University of Yamanashi 60
Not applicableActive Not RecruitingNCT04497285
What this trial is testing

Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 600
Testing effectiveness (Phase 2)UnknownNCT04636515
What this trial is testing

A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma

Who this might be right for
Locally Advanced or Metastatic Urothelial Cell Carcinoma
Shandong New Time Pharmaceutical Co., LTD 80
Testing effectiveness (Phase 2)Study completedNCT01016015
What this trial is testing

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Who this might be right for
Metastatic OsteosarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Osteosarcoma+2 more
National Cancer Institute (NCI) 178
Next Page